Tagged with M

GlaxoSmithKline Colombia Michael Sean Reilly: General Manager for Pharmaceuticals Juan Carlos Berbessi: Medical Director Maria del Pilar Rubio: Medical Manager for Vaccines Gustavo Zapata: Finance Director Juan Pablo Restrepo: Legal Affairs Manager What is the strategic role and importance of Colombia within the larger global framework of GlaxoSmithKline (GSK)? Michael Sean Reilly:…

Bristol-Myers Squibb Poland As Squibb Corporation and Bristol-Myers merged in 1989, Bristol-Myers Squibb has been officially operating in this market since that date, but the affiliate has a long history previous to that. What is the importance of Poland today for the group’s global strategy? About six years ago, there was a need…

Farmindustria & Laboratorio Volta As the CEO of Farmindustria since 1998, what would you say has been your recipe for the impressive success that the company has experienced, considering that Farmindustria represents 35% of all contract manufacturing activities in Chile? Our strongest key to success has certainly been the team that work’s here. Manufacturing…

UCB Phrama France Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company reoriented in the direction of biopharmaceuticals by moving away from chemicals and divesting from OTCs. As you have worked on the strategy and policy at headquarters in addition to…

Merck Chile What have been Merck’s major milestones and achievements for its pharmaceutical division since you took the reins? I have been managing the Pharma division of Merck since 2006 and the biggest milestone since then has definitely been the acquisition of Serono. In Chile Serono was previously represented by a local…

PGS Medical Statistics PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the niche PGS plays in the Brazilian market and the pharmaceutical sector? PGS is a company focused on statistics , data…

Menarini Pharma Netherlands Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What is the strategic role that the Netherlands and the Dutch market play for Menarini globally? When we started in 1996,…

Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…

Pharmaceutical Association of Malaysia (PhAMA) PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what are the core interests it stand for today? When the Association was first formed it represented most of the pharmaceutical…

Boehringer Ingelheim Italy The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could you describe the role of each entity together with its contribution to resources and growth? Boehringer Ingelheim itself is responsible…

Nefarma When it comes to the pharmaceutical and healthcare industries in the Netherlands, the country has one of the highest generic penetration rates in Europe, it does not have a strong manufacturing presence, and the market has been described as very regulated. Given all of this, what do you believe is…

Malaysian Organisation of Pharmaceutical Industries (MOPI) The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government been in creating an environment for growth in this industry? Malaysia stands out from the other ASEAN countries in terms…